Literature DB >> 23255516

Cancer risks for MLH1 and MSH2 mutation carriers.

James G Dowty1, Aung K Win, Daniel D Buchanan, Noralane M Lindor, Finlay A Macrae, Mark Clendenning, Yoland C Antill, Stephen N Thibodeau, Graham Casey, Steve Gallinger, Loic Le Marchand, Polly A Newcomb, Robert W Haile, Graeme P Young, Paul A James, Graham G Giles, Shanaka R Gunawardena, Barbara A Leggett, Michael Gattas, Alex Boussioutas, Dennis J Ahnen, John A Baron, Susan Parry, Jack Goldblatt, Joanne P Young, John L Hopper, Mark A Jenkins.   

Abstract

We studied 17,576 members of 166 MLH1 and 224 MSH2 mutation-carrying families from the Colon Cancer Family Registry. Average cumulative risks of colorectal cancer (CRC), endometrial cancer (EC), and other cancers for carriers were estimated using modified segregation analysis conditioned on ascertainment criteria. Heterogeneity in risks was investigated using a polygenic risk modifier. Average CRC cumulative risks at the age of 70 years (95% confidence intervals) for MLH1 and MSH2 mutation carriers, respectively, were estimated to be 34% (25%-50%) and 47% (36%-60%) for male carriers and 36% (25%-51%) and 37% (27%-50%) for female carriers. Corresponding EC risks were 18% (9.1%-34%) and 30% (18%-45%). A high level of CRC risk heterogeneity was observed (P < 0.001), with cumulative risks at the age of 70 years estimated to follow U-shaped distributions. For example, 17% of male MSH2 mutation carriers have estimated lifetime risks of 0%-10% and 18% have risks of 90%-100%. Therefore, average risks are similar for the two genes but there is so much individual variation about the average that large proportions of carriers have either very low or very high lifetime cancer risks. Our estimates of CRC and EC cumulative risks for MLH1 and MSH2 mutation carriers are the most precise currently available.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23255516      PMCID: PMC3887142          DOI: 10.1002/humu.22262

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  38 in total

1.  Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.

Authors:  Melissa C Southey; Mark A Jenkins; Leeanne Mead; Jonathan Whitty; Melanie Trivett; Andrea A Tesoriero; Letitia D Smith; Kim Jennings; Garry Grubb; Simon G Royce; Michael D Walsh; Melissa A Barker; Joanne P Young; Jeremy R Jass; D James B St John; Finlay A Macrae; Graham G Giles; John L Hopper
Journal:  J Clin Oncol       Date:  2005-08-22       Impact factor: 44.544

2.  The additive effect of p53 Arg72Pro and RNASEL Arg462Gln genotypes on age of disease onset in Lynch syndrome patients with pathogenic germline mutations in MSH2 or MLH1.

Authors:  Stefan Krüger; Christoph Engel; Andrea Bier; Ann-Sophie Silber; Heike Görgens; Elisabeth Mangold; Constanze Pagenstecher; Elke Holinski-Feder; Magnus von Knebel Doeberitz; Brigitte Royer-Pokora; Stefan Dechant; Christian Pox; Nils Rahner; Annegret Müller; Hans K Schackert
Journal:  Cancer Lett       Date:  2007-01-16       Impact factor: 8.679

Review 3.  Hereditary Non-Polyposis Colorectal Cancer: the rise and fall of a confusing term.

Authors:  Jeremy R Jass
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

4.  Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment.

Authors:  F Quehenberger; H F A Vasen; H C van Houwelingen
Journal:  J Med Genet       Date:  2005-06       Impact factor: 6.318

5.  GSTM1 and GSTT1 polymorphisms as modifiers of age at diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) in a homogeneous cohort of individuals carrying a single predisposing mutation.

Authors:  Rebecca Felix; Walter Bodmer; Nicola S Fearnhead; Lize van der Merwe; Paul Goldberg; Rajkumar S Ramesar
Journal:  Mutat Res       Date:  2006-12-01       Impact factor: 2.433

6.  Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer.

Authors:  Polly A Newcomb; John Baron; Michelle Cotterchio; Steve Gallinger; John Grove; Robert Haile; David Hall; John L Hopper; Jeremy Jass; Loïc Le Marchand; Paul Limburg; Noralane Lindor; John D Potter; Allyson S Templeton; Steve Thibodeau; Daniela Seminara
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-11-02       Impact factor: 4.254

7.  Genetic variation in genes for the xenobiotic-metabolizing enzymes CYP1A1, EPHX1, GSTM1, GSTT1, and GSTP1 and susceptibility to colorectal cancer in Lynch syndrome.

Authors:  Mala Pande; Christopher I Amos; Daniel R Osterwisch; Jinyun Chen; Patrick M Lynch; Russell Broaddus; Marsha L Frazier
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

8.  IGF1 is a modifier of disease risk in hereditary non-polyposis colorectal cancer.

Authors:  Stuart G Reeves; Dominique Rich; Cliff J Meldrum; Kim Colyvas; Grzegorz Kurzawski; Janina Suchy; Jan Lubinski; Rodney J Scott
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

9.  Cytochrome P450 17A1 and catechol O-methyltransferase polymorphisms and age at Lynch syndrome colon cancer onset in Newfoundland.

Authors:  Peter T Campbell; Laura Edwards; John R McLaughlin; Jane Green; H Banfield Younghusband; Michael O Woods
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

10.  Environmental factors and colorectal tumor risk in individuals with hereditary nonpolyposis colorectal cancer.

Authors:  Brenda Diergaarde; Hanneke Braam; Hans F Vasen; Fokko M Nagengast; Goos N P van Muijen; Frans J Kok; Ellen Kampman
Journal:  Clin Gastroenterol Hepatol       Date:  2007-06       Impact factor: 11.382

View more
  103 in total

1.  Is prostate cancer a Lynch syndrome cancer?

Authors:  Aung Ko Win
Journal:  Asian J Androl       Date:  2013-07-01       Impact factor: 3.285

Review 2.  Recent advances in Lynch syndrome.

Authors:  Leah H Biller; Sapna Syngal; Matthew B Yurgelun
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

3.  Worldwide Practice Patterns in Lynch Syndrome Diagnosis and Management, Based on Data From the International Mismatch Repair Consortium.

Authors:  Jennifer Y Pan; Robert W Haile; Allyson Templeton; Finlay Macrae; FeiFei Qin; Vandana Sundaram; Uri Ladabaum
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04-24       Impact factor: 11.382

4.  Choosing not to undergo predictive genetic testing for hereditary colorectal cancer syndromes: expanding our understanding of decliners and declining.

Authors:  Louise A Keogh; Heather Niven; Alison Rutstein; Louisa Flander; Clara Gaff; Mark Jenkins
Journal:  J Behav Med       Date:  2017-02-14

5.  Are the common genetic variants associated with colorectal cancer risk for DNA mismatch repair gene mutation carriers?

Authors:  Aung Ko Win; John L Hopper; Daniel D Buchanan; Joanne P Young; Albert Tenesa; James G Dowty; Graham G Giles; Jack Goldblatt; Ingrid Winship; Alex Boussioutas; Graeme P Young; Susan Parry; John A Baron; David Duggan; Steven Gallinger; Polly A Newcomb; Robert W Haile; Loïc Le Marchand; Noralane M Lindor; Mark A Jenkins
Journal:  Eur J Cancer       Date:  2013-02-22       Impact factor: 9.162

6.  Correlation of MLH1 polymorphisms, survival statistics, in silico assessment and gene downregulation with clinical outcomes among breast cancer cases.

Authors:  Saima Shakil Malik; Ayisha Zia; Sumaira Mubarik; Nosheen Masood; Sajid Rashid; Alice Sherrard; Muhammad Bilal Khan; Muhammad Tahir Khadim
Journal:  Mol Biol Rep       Date:  2019-11-08       Impact factor: 2.316

7.  Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.

Authors:  Daniel D Buchanan; Yen Y Tan; Michael D Walsh; Mark Clendenning; Alexander M Metcalf; Kaltin Ferguson; Sven T Arnold; Bryony A Thompson; Felicity A Lose; Michael T Parsons; Rhiannon J Walters; Sally-Ann Pearson; Margaret Cummings; Martin K Oehler; Penelope B Blomfield; Michael A Quinn; Judy A Kirk; Colin J Stewart; Andreas Obermair; Joanne P Young; Penelope M Webb; Amanda B Spurdle
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

8.  Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome.

Authors:  Aung Ko Win; Noralane M Lindor; Ingrid Winship; Katherine M Tucker; Daniel D Buchanan; Joanne P Young; Christophe Rosty; Barbara Leggett; Graham G Giles; Jack Goldblatt; Finlay A Macrae; Susan Parry; Matthew F Kalady; John A Baron; Dennis J Ahnen; Loic Le Marchand; Steven Gallinger; Robert W Haile; Polly A Newcomb; John L Hopper; Mark A Jenkins
Journal:  J Natl Cancer Inst       Date:  2013-02-05       Impact factor: 13.506

9.  The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.

Authors:  Sofia Maia; Marta Cardoso; Paula Paulo; Manuela Pinheiro; Pedro Pinto; Catarina Santos; Carla Pinto; Ana Peixoto; Rui Henrique; Manuel R Teixeira
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

10.  Female Hormonal Factors and the Risk of Endometrial Cancer in Lynch Syndrome.

Authors:  Seyedeh Ghazaleh Dashti; Rowena Chau; Driss Ait Ouakrim; Daniel D Buchanan; Mark Clendenning; Joanne P Young; Ingrid M Winship; Julie Arnold; Dennis J Ahnen; Robert W Haile; Graham Casey; Steven Gallinger; Stephen N Thibodeau; Noralane M Lindor; Loïc Le Marchand; Polly A Newcomb; John D Potter; John A Baron; John L Hopper; Mark A Jenkins; Aung Ko Win
Journal:  JAMA       Date:  2015-07-07       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.